Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic Characterization of Yellow Fever Virus Strain JSS, the Original South American Strain.

Viruses·2026

Same author

The Yellow Fever Virus Type-Specific Epitope Recognized by Monoclonal Antibody 2D12 Neutralizes Wild Type, but Not Live Attenuated 17D or French Neurotropic Vaccine Strains.

Vaccines·2026

Same author

Addressing the elephant in the room: Proceedings of the third annual Dengue Endgame Summit.

PLoS neglected tropical diseases·2026

Same author

Differences in Genetic Diversity between Early Isolates of Yellow Fever Virus Genotypes.

Emerging microbes & infections·2025

Same author

Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.

Vaccine·2025

Same author

Interaction of West Nile virus NS5 with orthoflavivirus SLA RNAs and their effects on viral replication and inhibition.

Journal of virology·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2025

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Vaccine value profile for Chikungunya.

Ximena Flandes¹, Clairissa A Hansen², Sunil Palani³

¹Department of Preventative Medicine and Population Health and University of Texas Medical Branch, Galveston, TX, United States.

|February 26, 2024

Summary

Chikungunya virus (CHIKV) causes significant chronic joint pain in about 40% of infected individuals. Developing a vaccine could greatly reduce disease burden, especially in low-income countries lacking treatments.

Keywords:

Chikungunya Vaccine Vaccine value Virus infection

More Related Videos

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

Related Experiment Videos

Last Updated: Jul 2, 2025

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

Area of Science:

* Virology and Epidemiology
* Public Health and Vaccine Development

Background:

* Chikungunya virus (CHIKV) causes Chikungunya (CHIK), a mosquito-borne illness with substantial acute and chronic morbidity.
* Chronic arthritis affects approximately 40% of CHIKV-infected individuals, leading to persistent pain and fatigue.
* Current CHIKV prevention relies on mosquito control, with no licensed antiviral drugs or vaccines available.

Purpose of the Study:

* To assess the potential public health, economic, and societal value of Chikungunya vaccines.
* To identify research and knowledge gaps in CHIKV vaccine development and implementation.
* To inform the value of vaccine-like products and those in the development pipeline.

Main Methods:

* A Vaccine Value Profile (VVP) for Chikungunya was developed.
* The VVP utilized existing, publicly available information.
* A working group of subject matter experts contributed to the VVP development.

Main Results:

* The VVP provides a holistic assessment of available data on CHIKV vaccines.
* It highlights the significant potential impact of vaccination on reducing disease burden and economic losses.
* The greatest benefits are anticipated in Low and Middle Income Countries (LMIC).

Conclusions:

* CHIKV vaccination holds significant promise for reducing the global burden of Chikungunya.
* Addressing knowledge gaps is crucial for realizing the full value of potential CHIKV vaccines.
* Vaccines could be particularly impactful in resource-limited settings disproportionately affected by CHIKV.